Login to Your Account



Takeover Next?

AMAG's High Feraheme Price Testing Iron Product's 'Metal'

By Randy Osborne


Monday, July 13, 2009
Hours after disclosing late-day news June 30 that his company's Feraheme at last won approval from the FDA, an exhilarated Brian J.G. Pereira, president and CEO of AMAG Pharmaceuticals Inc., told BioWorld Insight the iron-replacement would be priced "at a premium" to others on the market.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription